Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers found that the microRNA miR-1199-5p may reduce the expression of SRD5A2 in benign prostatic hyperplasia tissues, potentially contributing to the failure of 5-α reductase inhibitor therapy in some patients.

In this study, computational analysis identified six molecules, including Jamogenin, as effective in binding to the enzyme 5-alpha reductase (5-AR) from herbal extracts like nettle, saw palmetto, and fenugreek, suggesting potential for hair loss treatments.

This study found that methylation of the 5-AR 2 promoter region may lead to low or absent 5-AR 2 protein expression in some human adult prostate tissues.

This study demonstrated that methylation of the 5-alpha reductase type 2 (5-AR2) promoter is linked to reduced expression of the 5-AR2 protein, possibly explaining resistance to Finasteride in some BPH patients.

This study evaluated novel steroid compounds for their ability to inhibit 5α-reductase, showing that compound 16a significantly reduced rat prostate weight more than epristeride and exhibited excellent in vitro inhibitory potency, indicating its potential as a lead candidate for further benign prostatic hyperplasia drug research.

In an animal study, researchers observed that a newly synthesized deoxycholic acid derivative showed similar prostate protection effects to finasteride in Wistar rats while being less toxic.

This study found that a new deoxycholic acid derivative may offer a similar prostatoprotective effect to finasteride with lower toxicity in rat models.

This study identified that methylation of the 5-AR2 gene promoter is linked to reduced expression of 5-AR2 protein, which may explain why some BPH patients are resistant to finasteride treatment.

This study found that a topical solution of caffeine and minoxidil 2.5% was more effective in treating androgenetic alopecia than minoxidil 2.5% alone.

This study identified LY191704 as a specific noncompetitive inhibitor of human 5 alpha-reductase type 1, which may be useful in treating endocrine disorders related to DHT overproduction.

This review examines the pharmacological properties and potential clinical benefits of 5α‐reductase inhibition in prostate cancer but reports no new research findings.

This study concludes that rhesus macaques are a suitable model for testing the pharmacological properties of finasteride and other 5aR inhibitors, due to their biochemical similarity to humans.

In this study, dihydroartemisinin reduced prostate enlargement and related markers in a rat model of benign prostatic hyperplasia, suggesting its potential as a therapeutic agent.

This study used a novel HPLC-radiomatic flow scintillation system to measure 5α-reductase activity in dermal papillae from miniaturized hair follicles of the human occipital scalp, revealing significant variability in enzyme activity across samples.

This case report describes a 52-year-old man with androgenic alopecia who experienced improvement after adding low-dose dutasteride to long-term finasteride treatment when the initial therapy's effectiveness waned.

This article reviews updates on 5 alpha-reductase inhibitors for treating male pattern hair loss and presents no new clinical findings; the author aims to enhance understanding of these therapies.

In this study, Betula platyphylla extract, particularly fraction H3-2, promoted human derma papilla cell proliferation and increased expression of certain growth factors, suggesting potential benefits for hair loss prevention.

This study investigated the antioxidant and anti-inflammatory effects of the plant extract BLH308 and its potential to reduce hair loss, showing significant antioxidant activity in vitro.

This study found that in male Wistar rats, finasteride administration reduced neural cellular activity markers and 5-alpha reductase type 2 expression in brain tissue, with some recovery occurring after drug withdrawal, unlike persistent 5-alpha reductase type 2 suppression.

This study found that male 5α-reductase 2 knockout mice showed deficits in social dominance behaviors and reduced dopamine receptor binding in a brain region related to social ranking.

This study reported that 5 alpha-reductase type 2 is the predominant enzyme in pubic skin fibroblasts across normal men, women, and hirsute patients, suggesting potential treatment options for idiopathic hirsutism.

Accurate protein modeling can help develop new treatments for prostate cancer and other diseases.

This article reviews treatment options for male androgenetic alopecia, including minoxidil, 5 alpha reductase inhibitors, and hair transplantation, but reports no new clinical findings.

This research used computational methods to identify potential new treatments for benign prostatic hyperplasia, finding three compounds from Ghanaian plants with promising binding energy against 5alpha reductase 2 compared to existing drugs, yet further in vitro validation is necessary to confirm their efficacy.

This study found that specific residues in human steroid 5alpha-reductase types 1 and 2 influence substrate binding and resistance to the inhibitor Finasteride, with certain substitutions significantly affecting these interactions.

This study found that Avicennia marina extract significantly inhibited 5α-reductase type 1 activity in human hair dermal papilla cells, suggesting its potential use for treating androgenic alopecia.

In this study, researchers found that crude extracts from Avicennia marina and its component avicequinone C inhibit mechanisms contributing to androgenic alopecia in vitro, including 5α-reductase activity and DHT-AR interactions, potentially promoting hair growth and delaying the catagen phase in human dermal papilla cells.

This animal study found that finasteride, a 5-alpha reductase type 2 inhibitor, decreased dihydrotestosterone levels and c-Fos protein activation in the rat brain, but these effects may diminish after discontinuing the drug.

This review discusses the known effects of medications for benign prostatic hyperplasia on sexual function and mechanisms of dysfunction but reports no new clinical results.

This study found no significant increase in depression risk associated with taking five-alpha reductase inhibitors for benign prostatic hyperplasia or alopecia, although further studies are needed to confirm these findings.